Isabelle Zamfirescu, MD
Endocrinology, Diabetes & Metabolism · South Weymouth, MANPI 1881802031
Payments from drug & device makers
What this record shows
This record is dominated by other: $110 of the $139 with a category attached, or 78.9%. Abbott accounts for 78.9% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $110, more than ten times the $11 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MA, where the typical reported total is $583.
Across 4 payments — averaging $34.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$110
- Medtronic$24
- Lifescan, Inc.$6
What the payments were for
- Food & beverage$2921%
- Other$11079%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 1 | $110 |
| Medtronic | 2 | $24 |
| Lifescan, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139 in reported general payments places this provider in the 25th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 314 | $373,197 |
| TrulicityDulaglutide | 166 | $192,285 |
| MounjaroTirzepatide | 126 | $158,748 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 63 | $109,874 |
| JardianceEmpagliflozin | 97 | $92,323 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 131 | $77,212 |
| Tresiba Flextouch U-100Insulin Degludec | 78 | $63,703 |
| JanuviaSitagliptin Phosphate | 42 | $55,807 |
| Bydureon BciseExenatide Microspheres | 30 | $34,847 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $30,900 |
| Teriparatide | 12 | $29,001 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 167 | $27,884 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $25,916 |
| RybelsusSemaglutide | 11 | $24,280 |
| FarxigaDapagliflozin Propanediol | 26 | $22,014 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in South Weymouth
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.